Filtered By:
Specialty: Neurology
Drug: Coumadin
Education: Study

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 277 results found since Jan 2013.

Risk of Subarachnoid Hemorrhage and Early Case Fatality Associated With Outpatient Antithrombotic Drug Use Clinical Sciences
Conclusions— Outpatient antithrombotic drug use was associated with an increased risk of SAH, but no association was observed with early case fatality.
Source: Stroke - August 26, 2013 Category: Neurology Authors: Garbe, E., Kreisel, S. H., Behr, S. Tags: Heparin, Coumarins, Platelet function inhibitors, Cerebral Aneurysm, AVM, & Subarachnoid hemorrhage Clinical Sciences Source Type: research

Rivaroxaban versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation in Relation to the CHADS2 Score: A Subgroup Analysis of the J-ROCKET AF Trial
Conclusion: This subanalysis indicated that the safety and efficacy of rivaroxaban compared with warfarin were similar, regardless of CHADS2 score.
Source: Journal of Stroke and Cerebrovascular Diseases - August 19, 2013 Category: Neurology Authors: Masatsugu Hori, Masayasu Matsumoto, Norio Tanahashi, Shin-ichi Momomura, Shinichiro Uchiyama, Shinya Goto, Tohru Izumi, Yukihiro Koretsune, Mariko Kajikawa, Masaharu Kato, Hitoshi Ueda, Kazuma Iekushi, Satoshi Yamanaka, Masahiro Tajiri, J-ROCKET AF Study Tags: Original Articles Source Type: research

Warfarin-associated intracerebral hemorrhage: Volume, anticoagulation intensity and location
Conclusions: Patients with warfarin-associated ICH have a predilection for brainstem ICH. After adjustment for ICH location, no relationship between admission INR and hematoma volume was found.
Source: Journal of the Neurological Sciences - August 1, 2013 Category: Neurology Authors: Minmin Ma, Atte Meretoja, Leonid Churilov, Gagan J. Sharma, Søren Christensen, Xinfeng Liu, Louise Weir, Stephen M. Davis, Bernard Yan Tags: Original Articles Source Type: research

New Anticoagulants (Dabigatran, Apixaban, Rivaroxaban) for Stroke Prevention in Atrial Fibrillation
New oral anticoagulants have been found to be as efficacious as warfarin and safer in terms of intracranial bleeding. All patients with nonvalvular atrial fibrillation should receive antithrombotic therapy for stroke prevention. For those at low risk, antiplatelet therapy is probably sufficient. For those at intermediate or high risk, anticoagulation is superior to antiplatelet therapy. Four oral anticoagulants are currently approved for stroke and systemic embolism prevention in atrial fibrillation: warfarin, dabigatran, rivaroxaban, and apixaban. Management of bleeding complications while on the new agents remains an are...
Source: Neurologic Clinics - August 1, 2013 Category: Neurology Authors: Maria I. Aguilar, Ruth S. Kuo, William D. Freeman Source Type: research

Summary of evidence-based guideline: Periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology
Objective: To assess evidence regarding periprocedural management of antithrombotic drugs in patients with ischemic cerebrovascular disease. The complete guideline on which this summary is based is available as an online data supplement to this article. Methods: Systematic literature review with practice recommendations. Results and recommendations: Clinicians managing antithrombotic medications periprocedurally must weigh bleeding risks from drug continuation against thromboembolic risks from discontinuation. Stroke patients undergoing dental procedures should routinely continue aspirin (Level A). Stroke patients underg...
Source: Neurology - May 27, 2013 Category: Neurology Authors: Armstrong, M. J., Gronseth, G., Anderson, D. C., Biller, J., Cucchiara, B., Dafer, R., Goldstein, L. B., Schneck, M., Messe, S. R. Tags: Ultrasound, All Medical/Systemic disease, All Neuro-ophthalmology, All Cerebrovascular disease/Stroke, All Trauma SPECIAL ARTICLE Source Type: research

Reservations against new oral anticoagulants after stroke and cerebral bleeding
Abstract: Dabigatran, rivaroxaban, and apixaban are the new oral anticoagulants (NOAC) which have been investigated in patients with atrial fibrillation (AF) for primary and secondary prevention of stroke and thromboembolism. In these trials NOAC had a similar efficacy and safety profile compared to traditional vitamin-K-antagonists such as warfarin. We advise caution in the use of NOAC in patients with stroke or cerebral hemorrhage because of the following reasons:1) Patients with cerebral bleeding were excluded from the trials. 2) Stroke within 14days and severe stroke within 6months before screening were exclusion crite...
Source: Journal of the Neurological Sciences - April 29, 2013 Category: Neurology Authors: Claudia Stöllberger, Josef Finsterer Tags: Opinion Source Type: research

Bleeding Complications Associated with Warfarin Treatment in Ischemic Stroke Patients with Atrial Fibrillation: A Population-Based Cohort Study
Background: Bleeding events are the major obstacle to the widespread use of warfarin for secondary stroke prevention. Previous studies have not examined the use of risk stratification scores to estimate lifetime bleeding risk associated with warfarin treatment in a population-based setting. The purpose of this study is to determine the lifetime risk of bleeding events in ischemic stroke patients with atrial fibrillation (AF) undergoing warfarin treatment in a population-based cohort and to evaluate the use of bleeding risk scores to identify patients at high risk for lifetime bleeding events.Methods: The resources of the R...
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2013 Category: Neurology Authors: Raymond C.S. Seet, Alejandro A. Rabinstein, Teresa J.H. Christianson, George W. Petty, Robert D. Brown Tags: Original Articles Source Type: research

Anaemia on admission is associated with more severe intracerebral haemorrhage and worse outcomes
ConclusionsAnaemia on admission is associated with greater intracerebral haemorrhage severity and worse outcomes. The utility of transfusion remains unclear in this setting.
Source: International Journal of Stroke - March 7, 2013 Category: Neurology Authors: Miguel Bussière, Meera Gupta, Mukul Sharma, Dar Dowlatshahi, Jiming Fang, Rajat Dhar, Tags: Research Source Type: research

Leukoaraiosis is Associated with Short- and Long-term Mortality in Patients with Intracerebral Hemorrhage
Conclusions: In unselected patients in Southern Norway with first-ever ICH, severe leukoaraiosis is independently associated with both 30-day and long-term mortality in 30-day survivors. Warfarin is independently associated with 30-day mortality and coronary heart disease with long-term mortality in 30-day survivors. Recurrent ICH is more frequent after lobar ICH than after ICH in other locations.
Source: Journal of Stroke and Cerebrovascular Diseases - February 25, 2013 Category: Neurology Authors: Arnstein Tveiten, Unn Ljøstad, Åse Mygland, Halvor Naess Tags: Original Articles Source Type: research

Amino Terminal Pro-B-Type Natriuretic Peptide, Secondary Stroke Prevention, and Choice of Antithrombotic Therapy Clinical Sciences
Conclusions— For secondary stroke prevention, elevated NT-proBNP concentrations may identify a subgroup of ischemic stroke patients without known atrial fibrillation, about 5% based on the current study, who may benefit more from anticoagulants than antiplatelet agents. Clinical Trial Registration— This trial was not registered because enrollment began before 2005.
Source: Stroke - February 25, 2013 Category: Neurology Authors: Longstreth, W. T., Kronmal, R. A., Thompson, J. L. P., Christenson, R. H., Levine, S. R., Gross, R., Brey, R. L., Buchsbaum, R., Elkind, M. S. V., Tirschwell, D. L., Seliger, S. L., Mohr, J. P., deFilippi, C. R. Tags: Primary and Secondary Stroke Prevention Clinical Sciences Source Type: research

Is There an Increased Risk of Intracranial Hemorrhage When Treating Patients Who Are Currently on Dual Anti-Platelets with IV tPA? (P01.233)
CONCLUSIONS: In our cohort, there was no additional risk of hemorrhagic complications in patients on dual antiplatelet therapy who received IVtPA, prospective studies are needed to confirm this finding.Disclosure: Dr. Kung has nothing to disclose. Dr. Korsnack has nothing to disclose. Dr. Zaidi has nothing to disclose. Dr. Jumaa has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Kung, V., Korsnack, A., Zaidi, S., Jumaa, M. Tags: P01 Cerebrovascular Disease I Source Type: research

Warfarin treatment and thrombolysis: How to persuade procrastinators?
This study, which uses data from the American Heart Association Get With The Guidelines (GWTG)–Stroke Registry, concluded that there was no association between IV thrombolysis and symptomatic intracranial hemorrhage (SICH).1 These findings are in agreement with some2–4 but contrast with other studies (including 2 meta-analyses).5–8 The study by Xian et al. is the largest study to date drawing from hospitals throughout the United States, including 23,437 patients who received IV thrombolysis.1 Nearly 8% of these patients had prior warfarin use and 48.6% of the warfarin-treated patients who met the eligibil...
Source: Neurology - February 4, 2013 Category: Neurology Authors: Seet, R. C. S., Harrer, J. U. Tags: EDITORIALS Source Type: research

tPA and warfarin: Time to move forward
The appropriate use of IV tissue plasminogen activator (tPA) for patients with acute ischemic stroke remains an area of active discussion among health care professionals. Since its approval in the United States by the Food and Drug Administration in 1996, the medical community has continued to review and discuss the risks vs benefits of this important therapy. Two recent publications1,2 and accompanying editorials have refocused attention on the vexing issue of using IV tPA in patients taking warfarin. The Xian et al.1 study found a 1.1% absolute increase in the risk of intracranial hemorrhage (ICH) with warfarin use (5.7%...
Source: Neurology - February 4, 2013 Category: Neurology Authors: Alberts, M. J., Naidech, A. M. Tags: All Cerebrovascular disease/Stroke EDITORIALS Source Type: research